Blast count and cytogenetics correlate and are useful parameters for the evaluation of different phases in chronic myeloid leukemia

REFERENCES

• Beck Z, Kiss A, Toth FD, Szabo J, Bacsi A, Balogh E, Borbely A, Telek B, Kovacs E, Olah E, Rak K. Alterations of P53 and RB genes and the evolution of the accelerated phase of chronic myeloid leukemia. Leuk Lymphoma 200038:587 — 597.
   Google Scholar
• O'Dwyer ME, Mauro MJ, Blasdel C, Farnsworth M, Kurilik G, Hsieh YC, Mori M, Druker BJ. Clonal evolution and lack of cytogenetic response are adverse prognostic factors for hematologic relapse of chronic phase CML patients treated with Imatinib mesylate (STI571). Blood 2004;103(2):451 — 455.
   Google Scholar
• Jaffe E, Harris NL, Stein H, Vardiman JW. World Health Organization classification of tumours, pathology and genet-ics: tumours of haematopoietic and lymphopoetic tissues. Lyon: IARC Press; 2001.
   Google Scholar
• Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999;131:207–219.
   Google Scholar
• Griesshammer M, Heinze B, Hellmann A, Popp C, Anger B, Heil G, Bangerter M, Heimpel H. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol 1996;73:225 — 230.
   Google Scholar
• Kantarjian H, O'Brien S, Cortes J, Giles F, Thomas D, Kornblau S, Shan J, Beth RI\4, Keating M, Freireich E, Talpaz M. Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications. Cancer 2003;98: 81 —85.
   Google Scholar
• Acar H, Stewart J, Boyd E, Connor MJ. Identification of variant translocations in chronic myeloid leukemia by fluorescence in situ hybridization. Cancer Genet Cytogenet 1997;93:115–118.
   Google Scholar
• Ganesan TS, Rassool F, Guo AP, Th'ng KH, Dowding C, Hibbin JA, Young BD, White H, Kumaran TO, Galton DA. Rearrangement of the bcr gene in Philadelphia chromosome-negative chronic myeloid leukemia. Blood 1986;68:957 — 960 .
   Google Scholar
• Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451— 1464.
   Google Scholar
• Griesshammer M, Heinze B, Bangerter M, Heimpel H, Fliedner TM. Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia. J Mol Med 1997;75:836–838.
   Google Scholar
• Heim S, Mitelman F. Cancer cytogenetics, chromosomal and molecular genetic aberrations of tumour cells. 2nd ed. Basel: J. Wiley & Sons; 1995.
   Google Scholar
• Johansson B, Fioretos T, Mitelman F. Cytogenetic and molecular genetic evolution of chronic myeloid leukemia. Acta Haematol 2002;107:76–94.
   Google Scholar
• Cortes JE, Talpaz M, Giles F, O'Brien S, Rios MB, Shan J, Garcia-Manero G, Faderl S, Thomas DA, Wierda W, Ferrajoli A, Jeha S, Kantarjian HM. Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy. Blood 2003;101:3794–3800.
   Google Scholar
• Schoch C, Schnittger S, Bursch S, Gerstner D, Hochhaus A, Berger U, Hehlmann R, Hiddemann W, Haferlach T. Comparison of chromosome banding analysis, interphase-and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases. Leukemia 2002;16: 53 — 59.
   Google Scholar
• Schoch C, Haferlach T, Kern W, Schnittger S, Berger U, Hehlmann R, Hiddemann W, Hochhaus A. Occurrence of additional chromosome aberrations in chronic myeloid leukemia patients treated with imatinib mesylate. Leukemia 2003;17:461 —463.
   Google Scholar
• Mitelman F. An international system for human cytogenetic nomenclature: recommendations of the International Stand-ing Committee on Human Cytogenetic Nomenclature, Memphis, Tennessee, October 1994. Basle: Karger; 1995.
   Google Scholar
• Fader! S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med 1999;341:164 —172.
   Google Scholar
• Buesche G, Hehlmann R, Hecker H, Heimpel H, Heinze B, Schmeil A, Pfirrmann M, Gomez G, Tobler A, Herrmann H, Kappler M, Hasford J, Buhr T, Kreipe HH, Georgii A. Marrow fibrosis, indicator of therapy failure in chronic myeloid leukemia — prospective long-term results from a randomized-controlled trial. Leukemia 2003;17:2444 —2453.
   Google Scholar
• Kvasnicka HM, Thiele J, Schmitt-Graeff A, Diehl V, Niederle N, Schaefer HE. Impact of bone marrow morphol-ogy on multivariate risk classification in chronic myelogenous leukemia. Acta Haematol 2003;109:53 —56.
   Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Graeff A, Zirbes TK, Birnbaum F, Kressmann C, Melguizo-Grahmann M, Frack-enpohl H, Sprungmann C, Leder LD, Diehl V, Zankovich R, Schaefer HE, Niederle N, Fischer R. Bone marrow features and clinical findings in chronic myeloid leukemia—a comparative, multicenter, immunohistological and morpho-metric study on 614 patients. Leuk Lymphoma 2000;36: 295 —308.
   Google Scholar
• O'Brien SG, Guilhot F, Larson RA, Gathmann I, BaccaraniM, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994 — 1004.
   Google Scholar
• Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood 2002;99: 1928–1937.
   Google Scholar
• Kantarjian H1\4, Cortes J, O'Brien S, Giles FJ, Albitar M, Rios MB, Shan J, Fader! S, Garcia-Manero G, Thomas DA, Resta D, Talpaz M. Imatinib mesylate (5TI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002;99: 3547 —3553.
   Google Scholar
• Savage DG, Szydlo R1\4, Chase A, Apperley JF, Goldman JM. Bone marrow transplantation for chronic myeloid leukemia: the effects of differing criteria for defining chronic phase on probabilities of survival and relapse. Br J Haematol 1997;99: 30–35.
   Google Scholar
• Kantarjian HM, Keating MJ, Talpaz M, Walters RS, Smith TL, Cork A, McCredie KB, Freireich EJ. Chronic myelo-genous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987;83: 445 —454.
   Google Scholar
• Ruff P, Saragas E, Poulos M, Weaving A. Patterns of clonal evolution in transformed chronic myelogenous leukemia. Cancer Genet Cytogenet 1995;81:182 —184.
   Google Scholar